Nextremity Solutions, Inc. Announces Success of Initial Cases Using the InCore® TMT System
WARSAW, IND. (PRWEB) AUGUST 07, 2020
Nextremity Solutions, Inc., a strategic commercialization organization with a focus on the musculoskeletal space, located in “The Orthopedic Capital of the World,” Warsaw, Ind., recently completed the first several cases using its InCore TMT (Tarsometatarsal) System.
Building on the success of the proven design of the InCore Lapidus System, the InCore TMT System is a three-part construct intended for internal fixation in Lesser Tarsometatarsal Joint Arthrodesis (also known as Lisfranc Joint Fusion or 2nd/3rd Tarsometatarsal Fusion).
John G. Anderson, MD of Grand Rapids, Michigan stated, “InCore TMT is an innovative intramedullary bone fixation system for the midfoot that is easy to use, facilitates reduction of deformities. From my experience, these factors allow for early rehabilitation. The intramedullary aspect reduces the likelihood of prominent hardware that could necessitate further surgery in the form of hardware removal and is biomechanically ideal to withstand the stresses across the mid foot.”
The InCore TMT System allows for correction through the use of a Targeting Guide that provides distraction of the joint for visualization and joint preparation prior to fixation. The design of the Targeting Guide includes a built-in Compression-Distraction Fixture that provides compression parallel to the long axis of the first metatarsal.
“The unique design and intramedullary instrumentation allow for greater compression and tackles my concerns for early weight bearing after TMT joint fusion. In my opinion, early weight bearing and a high union rate leads to increased patient satisfaction,” added Donald R. Bohay, MD of Grand Rapids, Michigan.
Similar to the InCore Lapidus System, the InCore TMT System offers surgeons an intraosseous fixation option; an alternative to plating for this type of procedure. An intraosseous approach eliminates soft tissue contact which can lead to irritation in some patients since the implant is placed within bone and not on bone.
Nicholas Dodson, DPM of Valdosta, Georgia said, “The InCore TMT arthrodesis system utilizes an intraosseous fixation construct which completely eliminates the common postoperative complaint of painful hardware. The soft tissues overlying the TMT joint are very thin and not very accommodating to plates and screws in that area. By appropriately using the intraosseous fixation with InCore TMT arthrodesis, the surgeon is able to precisely place both compression screws and the titanium post with no fear of painful hardware or soft tissue irritation in the future. This is a game changer!”
Nextremity Solutions developed this technology with a team of surgeons that provide expertise in foot and ankle surgery. As part of its i3® Strategic Solutions process, this surgeon-driven approach ensures that input is received from surgeons in every stage of product development. This results in development of products that solve unmet surgeon and patient needs through technological advances not currently offered in the foot and ankle musculoskeletal space.
Michael S. Lee, DPM of Clive, Iowa concluded, “As one of the developing surgeons of the InCore TMT System, I truly believe that Nextremity Solutions has done an incredible job at listening to the needs of surgeons when it came to this system’s design and functionality. By taking what we’ve learned from the design and extensive use of the InCore Lapidus System implant and instrumentation, we were able to apply the same principles to tarsometatarsal fusion and provide an alternative to plating through an intraosseous approach. The amount of compression I am able to achieve provides the bone-to-bone apposition needed to promote healing and earlier weight bearing for my patients.”
The InCore TMT System is currently in a limited commercial launch.
To learn more about this and other products developed by Nextremity Solutions, visit http://www.nextremity.com.
About Nextremity Solutions, Inc.
Nextremity Solutions, Inc. is a privately held strategic commercialization organization with a focus on the musculoskeletal space, offering innovative solutions and Revenue Ready® products for various extremity musculoskeletal applications and for the benefit of our industry partners. The Company’s procedure-ready, sterile implant systems include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.